Odyssey Health signs non-binding LOI to merge with Speranza Therapeutics in all-stock deal

Odyssey Health, Inc.

Speranza's lead product ST Genesis is a wearable device for opioid withdrawal, FDA cleared, 93% response rate, targets $1.4B market.
Transaction makes Speranza a wholly owned subsidiary of Odyssey; Speranza management to remain post-closing.
Merger subject to due diligence, financing, and other conditions; deal terms were not disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.